Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is one of the stocks that are taking the center stage today as the company shares are trading 9.74% or 0.265 points higher from last closing price of $2.72, reaching $2.985 at last check. So what’s going on with RIGL shares anyway? The price has risen in 4 of the last 5 days and is up 60.95% over the past week. It will be exciting to see whether the stock manages to continue increasing or take a minor break for the next few days. The move came on weak volume too with far less shares changing hands than in a normal session. Trading activity as of this writing weakened by -2,208,367 shares, and in total 1.511 million shares valued at $4.509 million were seen changing hands compared with 3.719 million shares valued at $10.115 million recorded at the previous session. You should take into consideration that a falling volume on higher prices causes divergence and may be an early warning about possible changes in RIGL stock for the next couple of days.

Rigel Pharmaceuticals, Inc. (RIGL) shares have notched a 3-month gain of about 60.95%, but has still advanced 27.1% year to date. By comparison, the stock added 23.64% over the past 12 months, while it jumped 21.97% over the 1 month. The company’s market cap is around $473.39M, with its short interest ratio standing at 7.52%.

In the current trading session for RIGL, the stock witnessed two major price actions, it rose to a high of $3.1 and was down as much as $2.76 at one point. The high recorded is very low when compared to their 52-week high which is $1.56. The 52-week high is now at 8.18 distance from current price. Their recent low of $2.75 represents a 90.71% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for RIGL is $7.43, this is above the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.

The stock of Rigel Pharmaceuticals, Inc. earned $-0.28 per share in the trailing 12 months and has a P/E ratio of -10.66. You can compare it with that of similar companies in its industry to get a sense of whether the stock you’re looking to purchase is overvalued or undervalued. Its current price to earnings ratio is lower than the ones recorded by the industry which is 25.19 and lower compared to the sector’s average of 34.29. When the P/E ratio is low let’s say below 1.0, then the stock price is considered a good value. RIGL also has P/S multiple of 6.36. This is greater versus the 12 month P/S ratios of other companies in the same indutry. The peer average price to sales ratio is 2.83x.

RIGL‘s last price was up 39.69% as compared to the average trading price of 50 days recorded at $2.14 while enlarging the period to 200 trading days, the average closing price was $2.22. At present, there are 174.04 million in the total number of common shares owned by the public and among those 167.14 million shares have been available to trade. The percentage of shares being held by the company management was 0.28% while institutions stake was 92.5%. The company has generated negative returns on equity over the last 12 months (-52.7%). It managed to keep its gross profit margin at 98.9% over the past 12 months.

When assessing the full upside of the RIGL stock, there is another set of technicals that should be looked into and considered. Its 37.49% gain from moving average of $2.17 has brought about a positive sentiment when calculated over the last 20 days. The market has allocated a beta of 1.32 to the stock. With the beta been greater than one, this implies that the company shares are theoretically more volatile than the market, something that the traders definitely are keeping an eye on.

Most of the analysts surveyed by Thomson/First Call think quite highly of Rigel Pharmaceuticals, Inc. — 4 analysts rate the stock as a buy with another 0 rating it strong buy. There are 0 analysts who maintain a hold rating for the stock, with 0 giving it a sell rating. Analysts arrived at a 12-month price target of $7.5 on shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), which corresponds to 154.24% upside potential than its current market price of $2.985 and implies potential despite the recent advance in the price. However, their current target price has fallen from $7.5 a month ago and is up handily from the consensus target of $7.33 a quarter ago.

In the last five years, the EPS of the company has been roughly 15.5%. Though the percentage looks encouraging, extra headwinds are emerging as looking out over a next 5-year period, with analysts estimating that their earnings will decrease annually by 0%. The revenue of the company has risen at an average annualized rate of about 44.2 over the last five years. The company recently recorded an increase of 326.5%, but this figure is rather attractive.

Let’s briefly check the hedge fund interest towards RIGL stock. DNB Asset Management AS changed position in the company and now owns 143,561 shares worth $428,530, SEC documents show. Metropolitan Life Insurance Co NY cut assets in the stock as 52061.45 shares have been sold, reducing its stake by -17% to 43,211 shares which are currently valued at $128,985. In addition, Millennium Management LLC recently reported that it now owns 7,648,121 shares making a total of $22,829,641 based on the recent price. This refelects a change of 5309.8% in their ownership.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.